ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers

Genes Chromosomes and Cancer

Volumn 41, Issue 1, 2004, Pages 1-11

  Adem, Camilo ^a,b   Soderberg, Cheryl L ^a   Hafner, Kari ^a   Reynolds, Carol ^a   Slezak, Jeffrey M ^a   Sinclair, Colleen S ^a   Sellers, Thomas A ^a   Schaid, Daniel J ^a   Couch, Fergus ^a   Hartmann, Lynn C ^a   Jenkins, Robert B ^a  

^a MAYO CLINIC   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MYC PROTEIN; ONCOPROTEIN; RPS6KB1 PROTEIN; TBX2 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CANCER STAGING; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; FIBROCYSTIC BREAST DISEASE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DUPLICATION; GENE LOSS; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; MASTECTOMY; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST; BREAST NEOPLASMS; FEMALE; HETEROZYGOTE; HUMANS; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, ERBB-2; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; T-BOX DOMAIN PROTEINS;

EID: 3342996598     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20057     Document Type: Article

References (38)

1. Adem C, Reynolds CA, Soderberg CL, Slezak JM, McDonnell SK, Sebo TJ, Schaid DJ, Myers JL, Sellers TA, Hartmann LC, Jenkins RB. 2003. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer 97:1-11.
2. Beckmann MW, Niederacher D, Schnurch HG, Gusterson BA, Bender HG. 1997. Multistep carcinogenesis of breast cancer and tumor heterogeneity. J Mol Med 75:429-439.
3. Chappuis PO, Nethercot V, Foulkes WD. 2000. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 18:287-295.
4. Coquelle A, Rozier L, Dutrillaux B, Debatisse M. 2002. Induction of multiple double-strand breaks within an hsr by meganucleaseI-SceI expression or fragile site activation leads to formation of double minutes and other chromosomal rearrangements. Oncogene 21:7671-7679.
5. Cortez D, Wang Y, Qin J, Elledge SJ. 1999. Requirement of ATM-dependent phosphorylation of Brca1 in the DNA damage response to double-strand breaks. Science 286:1162-1166.
6. Deming SL, Nass SJ, Dickson RB, Trock BJ. 2000. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 83:1688-1695.
7. Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley PT, Loader S, Offit K, Robson M, Hampel H, Brener D, Winer EP, Clark S, Weber B, Strong LC, Rieger P, McClure M, Ward BE, Shattuck-Eidens D, Oliphant A, Skolnick MH, Thomas A. 1998. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16:2417-2425.
8. Greenblatt MS, Chappuis PO, Bond JP, Hamel N, Foulkes WD. 2001. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res 61:4092-4097.
9. Grushko TA, Blackwood MA, Schumm PL, Hagos FG, Adeyanju MO, Feldman MD, Sanders MO, Weber BL, Olopade OI. 2002. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res 62:1481-1488.
10. Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, Petty PM, Sellers TA, Johnson JL, McDonnell SK, Frost MH, Jenkins RB. 1999. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77-84.
11. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, Wilfond B, Borg A, Trent J. 2001. Gene-expression profiles in hereditary breast cancer. N Engl J Med 344:539-548.
12. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA, D'Andrea AD. 2002. Biallelic inactivation of BRCA2 in Fanconi anaemia. Science 297:606-609.
13. Kiyosawa H, Lensch MW, Chance PF. 1995. Analysis of the CMT1A-REP repeat: mapping crossover breakpoints in CMT1A and HNPP. Hum Mol Genet 4:2327-2334.
14. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF. 2002. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310-2318.
15. Larson PS, de las Morenas A, Cupples LA, Huang K, Rosenberg CL. 1998. Genetically abnormal clones in histologically normal breast tissue. Am J Pathol 152:1591-1598.
16. Lengauer C, Kinzler KW, Vogelstein B. 1998. Genetic instabilities in human cancers. Nature 396:643-649.
17. McDonnell SK, Schaid DJ, Myers JL, Grant CS, Donohue JH, Woods JE, Frost MH, Johnson JL, Sitta DL, Slezak JM, Crotty TB, Jenkins RB, Sellers TA, Hartmann LC. 2001. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 19:3938-3943.
18. Meraldi P, Honda R, Nigg EA. 2002. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO J 21:483-492.
19. Moynahan ME, Cui TY, Jasin M. 2001. Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a BRCA1 mutation. Cancer Res 61:4842-4850.
20. O'Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC. 1998. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 90:697-703.
21. Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN, Wold LE. 2002. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 77:148-154.
22. Persons DL, Borelli KA, Hsu PH. 1997. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol 10:720-727.
23. Rennstam K, Baldetorp B, Kytola S, Tanner M, Isola J. 2001. Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. Cancer Res 61:1214-1219.
24. Romanov SR, Kozakiewicz BK, Holst CR, Stampfer MR, Haupt LM, Tlsty TD. 2001. Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 409:633-637.
25. Rummukainen JK, Salininen T, Lundin J, Kytola S, Joensuu H, Isola JJ. 2001. Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array. Mod Pathol 14:1030-1035.
26. Savelyeva L, Claas A, Matzner I, Schlag P, Hofmann W, Scherneck S, Weber B, Schwab M. 2001. Constitutional genomic instability with inversions, duplications, and amplifications in 9p23-24 in BRCA2 mutation carriers. Cancer Res 61:5179-5185.
27. Sinclair CS, Adem C, Naderi A, Soderberg CL, Johnson M, Wu K, Wadum L, Couch VL, Sellers TA, Schaid D, Slezak J, Fredericksen Z, Ingle JN, Hartmann L, Jenkins RB, Couch FJ. 2002. TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors. Cancer Res 62:3587-3591.
28. Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingyarsson S, Karhu R, Tanner M, Isola J, Barkardottir RB, Borg A, Kallioniemi OP. 1997. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 57:1222-1227.
29. Tirkkonen M, Kainu T, Loman N, Johannsson OT, Olsson H, Barkardottir RB, Kallioniemi OP, Borg A. 1999. Somatic genetic alterations in BRCA2-associated and sporadic male breast cancer. Genes Chromosomes Cancer 24:56-61.
30. Tutt A, Gabriel A, Bertwistle D, Connor F, Paterson H, Peacock J, Ross G, Ashworth A. 1999. Absence of BRCA2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. Curr Biol 9:1107-1110.
31. Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, Wahl GM. 2002. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 9:1031-1044.
32. Vaziri SA, Tubbs RR, Darlington G, Casey G. 2001. Absence of CCND1 gene amplification in breast tumors of BRCA1 mutation carriers. Mol Pathol 54:259-263.
33. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J. 2000. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 14:927-939.
34. Wessels LF, van Welsem T, Hart AA, van't Veer LJ, Reinders MJ, Nederlof PM. 2002. Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res 62:7110-7117.
35. Xu X, Weaver Z, Linke SP, Li C, Gotay J, Wang XW, Harris CC, Ried T, Deng CX. 1999. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol. Cell 3:389-395.
36. Yin XY, Grove L, Datta NS, Long MW, Prochownik EV. 1999. C-myc overexpression and p53 loss cooperate to promote genomic instability. Oncogene 18:1177-1184.
37. Yuan SS, Lee SY, Chen G, Song M, Tomlinson GE, Lee EY. 1999. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res 59:3547-3551.
38. Zhang H, Somasundaram K, Peng Y, Tian H, Zhang H, Bi D, Weber BL, El-Deiry WS. 1998. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 16:1713-1721.